| Primary |
| Drug Use For Unknown Indication |
23.7% |
| Drug Exposure During Pregnancy |
11.2% |
| Tocolysis |
8.9% |
| Product Used For Unknown Indication |
7.7% |
| Nasopharyngitis |
7.1% |
| Intervertebral Disc Protrusion |
4.7% |
| Maternal Therapy To Enhance Foetal Lung Maturity |
4.1% |
| Headache |
3.6% |
| Back Pain |
3.0% |
| Chronic Sinusitis |
3.0% |
| Neonatal Respiratory Distress Syndrome |
3.0% |
| Sinusitis |
3.0% |
| Anaesthesia |
2.4% |
| Ill-defined Disorder |
2.4% |
| Pharyngitis |
2.4% |
| Sciatica |
2.4% |
| Tracheitis |
2.4% |
| Bronchitis |
1.8% |
| Bronchitis Acute |
1.8% |
| Chronic Obstructive Pulmonary Disease |
1.8% |
|
| Exposure During Pregnancy |
14.8% |
| Stevens-johnson Syndrome |
7.4% |
| Tremor |
7.4% |
| Injection Site Necrosis |
5.6% |
| No Adverse Event |
5.6% |
| Premature Baby |
5.6% |
| Visual Acuity Reduced |
5.6% |
| Dizziness |
3.7% |
| Hallucination, Visual |
3.7% |
| Hiccups |
3.7% |
| Iatrogenic Infection |
3.7% |
| Leukaemoid Reaction |
3.7% |
| Maternal Drugs Affecting Foetus |
3.7% |
| Maternal Exposure During Pregnancy |
3.7% |
| Nausea |
3.7% |
| Pain In Extremity |
3.7% |
| Pruritus |
3.7% |
| Rash Generalised |
3.7% |
| Rhabdomyolysis |
3.7% |
| Sleep Terror |
3.7% |
|
| Secondary |
| Drug Use For Unknown Indication |
17.9% |
| Bronchitis |
10.4% |
| Tocolysis |
10.0% |
| Angina Pectoris |
7.0% |
| Prophylaxis |
5.5% |
| Asthma |
5.0% |
| Epidural Anaesthesia |
4.5% |
| Depression |
4.0% |
| Hiv Infection |
4.0% |
| Cough |
3.5% |
| Body Temperature Increased |
3.0% |
| Chronic Obstructive Pulmonary Disease |
3.0% |
| Dyspnoea |
3.0% |
| Infection Prophylaxis |
3.0% |
| Musculoskeletal Pain |
3.0% |
| Pruritus |
3.0% |
| Rheumatoid Arthritis |
3.0% |
| Dermatitis Contact |
2.5% |
| Pemphigus |
2.5% |
| Sinusitis |
2.5% |
|
| Premature Baby |
15.4% |
| Surgery |
7.7% |
| Tendon Rupture |
7.7% |
| Vertigo |
7.7% |
| Visual Acuity Reduced |
7.7% |
| Pyrexia |
5.8% |
| Stroke Volume Decreased |
5.8% |
| Blood Glucose Increased |
3.8% |
| Intra-uterine Death |
3.8% |
| Maternal Exposure During Pregnancy |
3.8% |
| Pain |
3.8% |
| Periarthritis |
3.8% |
| Psychotic Disorder |
3.8% |
| Serotonin Syndrome |
3.8% |
| Tachycardia |
3.8% |
| Vomiting |
3.8% |
| Arthritis Bacterial |
1.9% |
| Constipation |
1.9% |
| Contusion |
1.9% |
| Convulsion |
1.9% |
|
| Concomitant |
| Drug Use For Unknown Indication |
11.2% |
| Hypertension |
10.5% |
| Product Used For Unknown Indication |
8.8% |
| Depression |
8.6% |
| Pain |
7.1% |
| Antiviral Treatment |
6.5% |
| Asthma |
6.5% |
| Prophylaxis |
5.2% |
| Rheumatoid Arthritis |
4.6% |
| Insomnia |
4.0% |
| Seborrhoeic Dermatitis |
3.4% |
| Hypersensitivity |
3.1% |
| Anxiety |
2.8% |
| Osteoporosis |
2.8% |
| Acquired Immunodeficiency Syndrome |
2.6% |
| Constipation |
2.6% |
| Dermatomyositis |
2.6% |
| Metastatic Renal Cell Carcinoma |
2.6% |
| Hypertriglyceridaemia |
2.4% |
| Hiv Infection |
2.2% |
|
| Weight Decreased |
9.6% |
| White Blood Cell Count Increased |
8.5% |
| Pulmonary Haemorrhage |
7.4% |
| Ileus Paralytic |
6.4% |
| Rash |
6.4% |
| Drug Exposure During Pregnancy |
5.3% |
| Respiratory Failure |
5.3% |
| Vomiting |
5.3% |
| White Blood Cell Count Decreased |
5.3% |
| Acute Generalised Exanthematous Pustulosis |
4.3% |
| Thrombocytopenia |
4.3% |
| Tremor |
4.3% |
| Urticaria |
4.3% |
| Weight Increased |
4.3% |
| Anaphylactic Shock |
3.2% |
| Epilepsy |
3.2% |
| Foetal Growth Restriction |
3.2% |
| Maculopathy |
3.2% |
| Maternal Exposure During Pregnancy |
3.2% |
| Nausea |
3.2% |
|
